Allogeneic bone marrow transplantation (BMT) is another indication. Patients who undergo BMT have their marrow cells ablated by chemotherapy, and for the first few months following BMT, experience a period of immunodeficiency. This results in insufficient production of IgG or other immunoglobulins. IVIG therapy helps IgG return to normal ranges, until the transplanted marrow starts functioning.

Related Links

BMT Links
http://www.bmtsupport.ie/links.html

NIH Consensus Development Program
http://consensus.nih.gov/1990/1990IntravenousImmunoglobulin080html.htm

WebMD
http://www.webmd.com/content/article/97/104125.htm

Science Daily Article
http://www.sciencedaily.com/releases/2004/12/041208234532.htm

BMT Overview
http://www.bmtsupport.ie/bmtoverview.html

Learn more about:
Antibody Deficiency Syndrome Bone Marrow/Solid Organ Transplant Cancer Chemotherapy Induced Immunosuppression Chronic Inflammatory Demyelinating Polyneuropathy Chronic Lymphocytic Leukemia Crohn's Disease Endometriosis Growth Hormone Deficiency Guillain-Barré Syndrome Hemophilia Hepatitis HIV Related ITP Hypogammaglobulinemia		Idiopathic Thrombocytopenia (ITP) Maternal/Pediatric/Adult Kawasaki Disease Male Factor Infertility Multifocal Motor Neuropathy Multiple Sclerosis Myasthenia Gravis (MG) Pediatric HIV Infection Pelvic Inflammatory Disease (PID) Polycystic Ovary Syndrome (PCOS) Psoriasis Rheumatoid Arthritis Scleroderma Subclass Immune Deficiency Systemic Lupus Erythematosus